A Multicenter, Randomized Controlled Phase III Clinical Trial of GP Induction Chemotherapy With TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma
A Multicenter, Randomized Controlled Phase III Clinical Trial of GP Induction Chemotherapy With TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Through randomized controlled phase III multicenter clinical trials, GP induction chemotherapy vs TPF regimen adjuvant chemotherapy combined with DDP concurrent chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma: the efficacy, toxicity and quality of life, and further improvement Survival rate and improve the quality of life.
Inclusion Criteria:
In the newly diagnosed patient, no radiotherapy or chemotherapy was performed before the start of the clinical trial.
Pathologically confirmed as non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated, ie WHO type II or III).
III, IVa patients (AJCC version 8 staging).
Male or non-pregnant women.
Age ≥ 18 and < 70 years old.
Functional status: Karnofsky scale (KPS) > 70.
White blood cells (WBC) ≥ 4 × 109.
/L, hemoglobin (HGB) ≥ 90 g / L, platelets (PLT) ≥ 100 × 109 / L (or within the normal range of the laboratory)
Liver function: alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 1.5 times the upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN.
Renal function: creatinine clearance ≥ 60ml / min or serum creatinine ≤ 1.5 × ULN.
The patient has signed an informed consent form.
Exclusion Criteria:
jinf8865@yeah.net0851-86512802
lilyuanyuan@qq.com0851-86512802
Guiyang, Guizhou 550000, China
lilyuanyuan@qq.com085186512802